Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

NCT03904693 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

187

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)

Interventions

DRUG: FDC macitentan/tadalafil
DRUG: Macitentan 10 mg
DRUG: Tadalafil 40 mg
DRUG: Placebo FDC
DRUG: Placebo macitentan
DRUG: Placebo tadalafil

Sponsor

Actelion